Even though we assume that primarily patients with existing metastases would benefit from CNS screening, our retrospective data analysis indicated that specific high-risk groups, such as HER2+ BC patients could also benefit from screening in early stages in the absence of extracranial disease. Here, ERBB2 is linked to breast cancer.